Granzyme M: behind enemy lines

Cell Death and Differentiation

Volumn 21, Issue 3, 2014, Pages 359-368

  De Poot, S A H ^a   Bovenschen, N ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

apoptosis; CMV; cytotoxic lymphocytes; granzyme M; inflammation; serine protease

Indexed keywords

GRANZYME;

ANIMAL; CELL DEATH; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL DEATH; GRANZYMES; HUMANS;

EID: 84893875846     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.189     Document Type: Review

References (103)

1. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 256: 58-66
2. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010; 17: 616-623
3. Lieberman J. Anatomy of a murder: How cytotoxic T cells and NK cells are activated, develop, and eliminate their targets. Immunol Rev 2010; 235: 5-9
4. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323-370
5. Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA. Perforin: Structure, function, and role in human immunopathology. Immunol Rev 2010; 235: 35-54
6. Grossman WJ, Revell PA, Lu ZH, Johnson H, Bredemeyer AJ, Ley TJ. The orphan granzymes of humans and mice. Curr Opin Immunol 2003; 15: 544-552
7. Sattar R, Ali SA, Abbasi A. Bioinformatics of granzymes: Sequence comparison and structural studies on granzyme family by homology modeling. Biochem Biophys Res Commun 2003; 308: 726-735
8. Bovenschen N, Kummer JA. Orphan granzymes find a home. Immunol Rev 2010; 235: 117-127
9. de Koning PJ, Kummer JA, Bovenschen N. Biology of granzyme M: A serine protease with unique features. Crit Rev Immunol 2009; 29: 307-315
10. Smyth MJ, Wiltrout T, Trapani JA, Ottaway KS, Sowder R, Henderson LE et al. Purification and cloning of a novel serine protease, RNK-Met-1, from the granules of a rat natural killer cell leukemia. J Biol Chem 1992; 267: 24418-24425
11. Smyth MJ, Sayers TJ, Wiltrout T, Powers JC, Trapani JA. Met-Ase: Cloning and distinct chromosomal location of a serine protease preferentially expressed in human natural killer cells. J Immunol 1993; 151: 6195-6205
12. Kelly JM, O'Connor MD, Hulett MD, Thia KY, Smyth MJ. Cloning and expression of the recombinant mouse natural killer cell granzyme Met-Ase-1. Immunogenetics 1996; 44: 340-350
13. Baker E, Sutherland GR, Smyth MJ. The gene encoding a human natural killer cell granule serine protease, Met-Ase 1, maps to chromosome 19p13.3. Immunogenetics 1994; 39: 294-295
14. Pilat D, Fink T, Obermaier-Skrobanek B, Zimmer M, Wekerle H, Lichter P et al. The human Met-Ase gene (GZMM): Structure, sequence, and close physical linkage to the serine protease gene cluster on 19p13.3. Genomics 1994; 24: 445-450
15. Thia KY, Jenkins NA, Gilbert DJ, Copeland NG, Smyth MJ. The natural killer cell serine protease gene Lmet1 maps to mouse chromosome 10. Immunogenetics 1995; 41: 47-49
16. Zimmer M, Medcalf RL, Fink TM, Mattmann C, Lichter P, Jenne DE. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc Natl Acad Sci 1992; 89: 8215-8219
17. Smyth MJ, Hulett MD, Thia KY, Young HA, Sayers TJ, Carter CR et al. Cloning and characterization of a novel NK cell-specific serine protease gene and its functional 5'-flanking sequences. Immunogenetics 1995; 42: 101-111
18. McGuire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem 1993; 268: 2458-2467
19. Smyth MJ, O'Connor MD, Trapani JA. Granzymes: A variety of serine protease specificities encoded by genetically distinct subfamilies. J Leukoc Biol 1996; 60: 555-562
20. Smyth MJ, O'Connor MD, Trapani JA, Kershaw MH, Brinkworth RI. A novel substratebinding pocket interaction restricts the specificity of the human NK cell-specific serine protease, Met-Ase-1. J Immunol 1996; 156: 4174-4181
21. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci USA 1999; 96: 8627-8632
22. Kummer JA, Kamp AM, Citarella F, Horrevoets AJ, Hack CE. Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C. J Biol Chem 1996; 271: 9281-9286
23. Rukamp BJ, Kam CM, Natarajan S, Bolton BW, Smyth MJ, Kelly JM et al. Subsite specificities of granzyme M: A study of inhibitors and newly synthesized thiobenzyl ester substrates. Arch Biochem Biophys 2004; 422: 9-22
24. Wu L, Wang L, Hua G, Liu K, Yang X, Zhai Y et al. Structural basis for proteolytic specificity of the human apoptosis-inducing granzyme M. J Immunol 2009; 183: 421-429
25. Galvin JP, Spaeny-Dekking LH, Wang B, Seth P, Hack CE, Froelich CJ. Apoptosis induced by granzyme B-glycosaminoglycan complexes: Implications for granulemediated apoptosis in vivo. J Immunol 1999; 162: 5345-5350
26. Smyth MJ, O'Connor MD, Kelly JM, Ganesvaran P, Thia KY, Trapani JA. Expression of recombinant human Met-Ase-1: A NK cell-specific granzyme. Biochem Biophys Res Commun 1995; 217: 675-683
27. Khurshid R, Saleem M, Akhtar MS, Salim A. Granzyme M: Characterization with sites of post-Translational modification and specific sites of interaction with substrates and inhibitors. Mol Biol Rep 2011; 38: 2953-2960
28. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967; 27: 157-162
29. Mahrus S, Kisiel W, Craik CS. Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J Biol Chem 2004; 279: 54275-54282
30. Mahrus S, Craik CS. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol 2005; 12: 567-577
31. de Poot SA, Westgeest M, Hostetter DR, Van Damme P, Plasman K, Demeyer K et al. Human and mouse granzyme M display divergent and species-specific substrate specificities. Biochem J 2011; 437: 431-442
32. de Poot SA, Lai KW, van der Wal L, Plasman K, Van Damme P, Porter AC et al. Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspasedependent apoptosis. Cell Death Differ 2014; 21: 416-426
33. Cullen SP, Afonina IS, Donadini R, Luthi AU, Medema JP, Bird PI et al. Nucleophosmin is cleaved and inactivated by the cytotoxic granule protease granzyme M during natural killer cell-mediated killing. J Biol Chem 2009; 284: 5137-5147
34. Wang S, Xia P, Shi L, Fan Z. FADD cleavage by NK cell granzyme M enhances its selfassociation to facilitate procaspase-8 recruitment for auto-processing leading to caspase cascade. Cell Death Differ 2012; 19: 605-615
35. de Poot SA, Lai KW, Hovingh ES, Bovenschen N. Granzyme M cannot induce cell death via cleavage of mouse FADD. Apoptosis 2013; 18: 533-534
36. Smyth MJ, Browne KA, Kinnear BF, Trapani JA, Warren HS. Distinct granzyme expression in human CD3- CD56+ large granular- and CD3- CD56+ small high density-lymphocytes displaying non-MHC-restricted cytolytic activity. J Leukoc Biol 1995; 57: 88-93
37. Sayers TJ, Brooks AD, Ward JM, Hoshino T, Bere WE, Wiegand GW et al. The restricted expression of granzyme M in human lymphocytes. J Immunol 2001; 166: 765-771
38. Bots M, Kolfschoten IG, Bres SA, Rademaker MT, de Roo GM, Kruse M et al. SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood 2005; 105: 1153-1161
39. Bade B, Boettcher HE, Lohrmann J, Hink-Schauer C, Bratke K, Jenne DE et al. Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes. Int Immunol 2005; 17: 1419-1428
40. de Koning PJ, Tesselaar K, Bovenschen N, Colak S, Quadir R, Volman TJ et al. The cytotoxic protease granzyme M is expressed by lymphocytes of both the innate and adaptive immune system. Mol Immunol 2010; 47: 903-911
41. van Domselaar R, de Poot SA, Remmerswaal EB, Lai KW, Ten Berge IJ, Bovenschen N. Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication. Cell Death Differ 2013; 20: 419-429
42. Zhang B, Zhang J, Tian Z. Comparison in the effects of IL-2, IL-12, IL-15 and IFNalpha on gene regulation of granzymes of human NK cell line NK-92. Int Immunopharmacol 2008; 8: 989-996
43. Kelly JM, Waterhouse NJ, Cretney E, Browne KA, Ellis S, Trapani JA et al. Granzyme M mediates a novel form of perforin-dependent cell death. J Biol Chem 2004; 279: 22236-22242
44. Hu D, Liu S, Shi L, Li C, Wu L, Fan Z. Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells. J Biol Chem 2010; 285: 18326-18335
45. Hua G, Zhang Q, Fan Z. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J Biol Chem 2007; 282: 20553-20560
46. Lu H, Hou Q, Zhao T, Zhang H, Zhang Q, Wu L et al. Granzyme M directly cleaves inhibitor of caspase-Activated DNase (CAD) to unleash CAD leading to DNA fragmentation. J Immunol 2006; 177: 1171-1178
47. Bovenschen N, de Koning PJ, Quadir R, Broekhuizen R, Damen JM, Froelich CJ et al. NK cell protease granzyme M targets alpha-Tubulin and disorganizes the microtubule network. J Immunol 2008; 180: 8184-8191
48. Timmer JC, Salvesen GS. Caspase substrates. Cell Death Differ 2007; 14: 66-72
49. van Domselaar R, Quadir R, van der Made AM, Broekhuizen R, Bovenschen N. All human granzymes target hnRNP K that is essential for tumor cell viability. J Biol Chem 2012; 287: 22854-22864
50. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC Granzyme B: A natural born killer. Immunol Rev 2003; 193: 31-38
51. Trapani JA, Sutton VR. Granzyme B: Oro-Apoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003; 15: 533-543
52. Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S et al. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998; 18: 6387-6398
53. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001; 98: 11515-11520
54. Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: A novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002; 99: 232-237
55. van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005; 11: 6400-6407
56. Andrade F, Fellows E, Jenne DE, Rosen A, Young CS. Granzyme H destroys the function of critical adenoviral proteins required for viral DNA replication and granzyme B inhibition. Embo J 2007; 26: 2148-2157
57. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-37
58. Lowin B, Beermann F, Schmidt A, Tschopp J. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994; 91: 11571-11575
59. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192: 755-760
60. Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proc Natl Acad Sci USA 2009; 106: 9809-9814
61. Brennan AJ, Chia J, Trapani JA, Voskoboinik I. Perforin deficiency and susceptibility to cancer. Cell Death Differ 2010; 17: 607-615
62. Davis JE, Smyth MJ, Trapani JA. Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-Tumor capacity. Eur J Immunol 2001; 31: 39-47
63. Smyth MJ, Street SE, Trapani JA. Cutting edge: Granzymes A and B are not essential for perforin-mediated tumor rejection. J Immunol 2003; 171: 515-518
64. Pao LI, Sumaria N, Kelly JM, van Dommelen S, Cretney E, Wallace ME et al. Functional analysis of granzyme M and its role in immunity to infection. J Immunol 2005; 175: 3235-3243
65. Pegram HJ, Haynes NM, Smyth MJ, Kershaw MH, Darcy PK. Characterizing the antitumor function of adoptively transferred NK cells in vivo. Cancer Immunol Immunother 2010; 59: 1235-1246
66. van Domselaar R, Bovenschen N. Cell death-independent functions of granzymes: Hit viruses where it hurts. Rev Med Virol 2011; 21: 301-314
67. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008; 322: 268-271
68. Zhong C, Li C, Wang X, Toyoda T, Gao G, Fan Z. Granzyme K inhibits replication of influenza virus through cleaving the nuclear transport complex importin alpha1/beta dimer of infected host cells. Cell Death Differ 2012; 19: 882-890
69. Romero V, Fellows E, Jenne DE, Andrade F. Cleavage of La protein by granzyme H induces cytoplasmic translocation and interferes with La-mediated HCV-IRES translational activity. Cell Death Differ 2009; 16: 340-348
70. Tang H, Li C, Wang L, Zhang H, Fan Z. Granzyme H of cytotoxic lymphocytes is required for clearance of the hepatitis B virus through cleavage of the hepatitis B virus X protein. J Immunol 2012; 188: 824-831
71. Anthony DA, Andrews DM, Watt SV, Trapani JA, Smyth MJ. Functional dissection of the granzyme family: Cell death and inflammation. Immunol Rev 2010; 235: 73-92
72. van Domselaar R, Philippen LE, Quadir R, Wiertz EJ, Kummer JA, Bovenschen N. Noncytotoxic inhibition of cytomegalovirus replication through NK cell protease granzyme M-mediated cleavage of viral phosphoprotein 71. J Immunol 2010; 185: 7605-7613
73. Bresnahan WA, Shenk TE. UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells. Proc Natl Acad Sci USA 2000; 97: 14506-14511
74. Bovenschen N, Spijkers SN, Wensink AC, Schellens IM, van Domselaar R, van Baarle D. Elevated granzyme M-expressing lymphocytes during cytomegalovirus latency and reactivation after allogeneic stem cell transplantation. Clin Immunol 2013; 150: 1-11
75. Dohner K, Nagel CH, Sodeik B. Viral stop-And-go along microtubules: Taking a ride with dynein and kinesins. Trends Microbiol 2005; 13: 320-327
76. Mai RT, Yeh TS, Kao CF, Sun SK, Huang HH, Wu Lee YH. Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression. Oncogene 2006; 25: 448-462
77. Huang WH, Yung BY, Syu WJ, Lee YH. The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication. J Biol Chem 2001; 276: 25166-25175
78. Kondapi AK, Satyanarayana N, Saikrishna AD. A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes. Arch Biochem Biophys 2006; 450: 123-132
79. Lokeswara Balakrishna S, Satyanarayana N, Kondapi AK. Involvement of human topoisomerase II isoforms in HIV-1 reverse transcription. Arch Biochem Biophys 2013; 532: 91-102
80. Advani SJ, Weichselbaum RR, Roizman B. Herpes simplex virus 1 activates cdc2 to recruit topoisomerase II alpha for post-DNA synthesis expression of late genes. Proc Natl Acad Sci USA 2003; 100: 4825-4830
81. Lin YC, Li J, Irwin CR, Jenkins H, DeLange L, Evans DH. Vaccinia virus DNA ligase recruits cellular topoisomerase II to sites of viral replication and assembly. J Virol 2008; 82: 5922-5932
82. Lee CP, Chen JY, Wang JT, Kimura K, Takemoto A, Lu CC et al. Epstein-Barr virus BGLF4 kinase induces premature chromosome condensation through activation of condensin and topoisomerase II. J Virol 2007; 81: 5166-5180
83. Froelich CJ, Pardo J, Simon MM. Granule-Associated serine proteases: Granzymes might not just be killer proteases. Trends Immunol 2009; 30: 117-123
84. Romero V, Andrade F. Non-Apoptotic functions of granzymes. Tissue Antigens 2008; 71: 409-416
85. Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem 2005; 280: 23549-23558
86. Hiebert PR, Boivin WA, Abraham T, Pazooki S, Zhao H, Granville DJ. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp Gerontol 2011; 46: 489-499
87. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 2008; 29: 720-733
88. Irmler M, Hertig S, MacDonald HR, Sadoul R, Becherer JD, Proudfoot A et al. Granzyme A is an interleukin 1 beta-converting enzyme. J Exp Med 1995; 181: 1917-1922
89. Joeckel LT, Wallich R, Martin P, Sanchez-Martinez D, Weber FC, Martin SF et al. Mouse granzyme K has pro-inflammatory potential. Cell Death Differ 2011; 18: 1112-1119
90. Anthony DA, Andrews DM, Chow M, Watt SV, House C, Akira S et al. A role for granzyme M in TLR4-driven inflammation and endotoxicosis. J Immunol 2010; 185: 1794-1803
91. Hollestelle MJ, Lai KW, van Deuren M, Lenting PJ, de Groot PG, Sprong T et al. Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS One 2011; 6: E24216
92. de Koning PJ, Kummer JA, de Poot SA, Quadir R, Broekhuizen R, McGettrick AF et al. Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. PLoS One 2011; 6: E22645
93. Sun J, Ooms L, Bird CH, Sutton VR, Trapani JA, Bird PI. A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). J Biol Chem 1997; 272: 15434-15441
94. Bots M, VANB L, Rademaker MT, Offringa R, Medema JP. Serpins prevent granzymeinduced death in a species-specific manner. Immunol Cell Biol 2006; 84: 79-86
95. Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM, Pemberton PA et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem 1997; 272: 1849-1855
96. Silverman GA, Whisstock JC, Askew DJ, Pak SC, Luke CJ, Cataltepe S et al. Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis. Cell Mol Life Sci 2004; 61: 301-325
97. Wang L, Li Q, Wu L, Liu S, Zhang Y, Yang X et al. Identification of SERPINB1 as a physiological inhibitor of human granzyme H. J Immunol 2013; 190: 1319-1330
98. Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271: 27802-27809
99. de Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H et al. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol 1998; 19: 505-516
100. Cataltepe S, Gornstein ER, Schick C, Kamachi Y, Chatson K, Fries J et al. Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas. J Histochem Cytochem 2000; 48: 113-122
101. Hsu KF, Huang SC, Shiau AL, Cheng YM, Shen MR, Chen YF et al. Increased expression level of squamous cell carcinoma antigen 2 and 1 ratio is associated with poor prognosis in early-stage uterine cervical cancer. Int J Gynecol Cancer 2007; 17: 174-181
102. Deng Z, Hasegawa M, Yamashita Y, Matayoshi S, Kiyuna A, Agena S et al. Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci 2012; 103: 2127-2134
103. van Domselaar R, de Poot SA, Bovenschen N. Proteomic profiling of proteases: Tools for granzyme degradomics. Expert Rev Proteomics 2010; 7: 347-359